A phase III study of Iressa [gefitinib] in combination with intravesical BCG versus intravesical BCG alone in high risk superficial transitional cell carcinoma of the bladder.

Trial Profile

A phase III study of Iressa [gefitinib] in combination with intravesical BCG versus intravesical BCG alone in high risk superficial transitional cell carcinoma of the bladder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Gefitinib (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Jan 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.
    • 09 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top